Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Kwon, J H ^a   Jang, J W ^a   Lee, S ^b   Lee, J ^b   Chung, K W ^a   Lee, Y S ^a   Choi, J Y ^a  

^a Bupyeong gu   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

entecavir; hepatitis B e antigen; quantification; virologic response

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; TREATMENT RESPONSE; VIROLOGIC RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84855849161     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01509.x     Document Type: Article

References (24)

1. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
2. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010. (Pubitemid 43357804)
3. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-79.
4. Lau GK,. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int 2010; 30: 512-520.
5. Kau A, Vermehren J, Sarrazin C,. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651.
6. Zeuzem S, Gane E, Liaw YK, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
7. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897. (Pubitemid 47127032)
8. Kobayashi M, Suzuki F, Akuta N, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007; 79: 1472-1477. (Pubitemid 47328735)
9. Ozaras R, Tabak F, Tahan V, et al. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 2008; 53: 2995-2998.
10. Borgniet O, Parvaz P, Bouix C, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol 2009; 81: 1336-1342.
11. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
12. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
13. Chen J, Wang Z, Guo Y, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009; 81: 88-91.
14. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C,. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18: 1306-1312. (Pubitemid 23348414)
15. Bernard F, Raymond G, Willems B, Villeneuve JP,. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997; 4: 265-272. (Pubitemid 127733433)
16. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW,. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000; 7: 382-386.
17. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-434. (Pubitemid 351280710)
18. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-222. (Pubitemid 37506037)
19. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
20. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.
21. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
22. Liaw YF, Leung N, Kao JH, et al., for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
23. Gish RG, Locarnini SA,. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676. (Pubitemid 43825809)
24. Laperche S, Thibault V, Bouchardeau F, et al. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol 2006; 44: 3600-3607. (Pubitemid 46768819)